MX374547B - Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer. - Google Patents

Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer.

Info

Publication number
MX374547B
MX374547B MX2015003416A MX2015003416A MX374547B MX 374547 B MX374547 B MX 374547B MX 2015003416 A MX2015003416 A MX 2015003416A MX 2015003416 A MX2015003416 A MX 2015003416A MX 374547 B MX374547 B MX 374547B
Authority
MX
Mexico
Prior art keywords
cancer treatment
specific immunotherapies
improve specific
invention relate
cancer
Prior art date
Application number
MX2015003416A
Other languages
English (en)
Spanish (es)
Other versions
MX2015003416A (es
Inventor
Anatole Klyosov
Eliezer Zomer
Peter G Traber
Stefanie N Linch
William L Redmond
Original Assignee
Galectin Therapeutics Inc
Providence Health & Services Oregon D/B/A Earle A Chiles Res Institute Of The Robert W Franz Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc, Providence Health & Services Oregon D/B/A Earle A Chiles Res Institute Of The Robert W Franz Cancer filed Critical Galectin Therapeutics Inc
Publication of MX2015003416A publication Critical patent/MX2015003416A/es
Publication of MX374547B publication Critical patent/MX374547B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015003416A 2012-09-17 2013-09-17 Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer. MX374547B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261701914P 2012-09-17 2012-09-17
US201361756818P 2013-01-25 2013-01-25
US201361759532P 2013-02-01 2013-02-01
PCT/US2013/060182 WO2014043708A1 (en) 2012-09-17 2013-09-17 Method for enhancing specific immunotherapies in cancer treatment

Publications (2)

Publication Number Publication Date
MX2015003416A MX2015003416A (es) 2015-10-29
MX374547B true MX374547B (es) 2025-03-06

Family

ID=50278770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003416A MX374547B (es) 2012-09-17 2013-09-17 Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer.

Country Status (14)

Country Link
US (2) US9872909B2 (enExample)
EP (1) EP2900061B1 (enExample)
JP (1) JP6415437B2 (enExample)
KR (1) KR102207767B1 (enExample)
CN (1) CN104812244B (enExample)
AU (1) AU2013315019B2 (enExample)
BR (1) BR112015005772A2 (enExample)
CA (1) CA2885970C (enExample)
DK (1) DK2900061T3 (enExample)
ES (1) ES2773921T3 (enExample)
IL (1) IL237752B (enExample)
MX (1) MX374547B (enExample)
WO (1) WO2014043708A1 (enExample)
ZA (1) ZA201501914B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
KR101968370B1 (ko) 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10752705B2 (en) 2014-07-09 2020-08-25 Cadena Bio, Inc. Oligosaccharide compositions and methods for producing thereof
EP4205553A1 (en) 2015-01-26 2023-07-05 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
RU2017142008A (ru) * 2015-05-21 2019-06-24 Эллигейтор Биосайенс Аб Новые полипептиды
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN116333138A (zh) 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法
PT3376857T (pt) * 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CA3023820A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11603394B2 (en) 2016-10-04 2023-03-14 University Of Florida Research Foundation, Incorporated Targeted effector proteins and uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018102567A1 (en) * 2016-12-01 2018-06-07 Yale University Prediction of response to immune-modulatory therapies
CN109232738B (zh) * 2017-07-11 2021-11-09 南京金斯瑞生物科技有限公司 一种抗人ox40单克隆抗体及其应用
AU2018308088B2 (en) * 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
KR102089241B1 (ko) * 2018-02-05 2020-03-16 한국과학기술원 암 환자에서 면역 치료 효과를 예측하는 방법
JP2021529163A (ja) 2018-06-29 2021-10-28 グリコス バイオメディカル オーワイ コンジュゲート
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
WO2021163802A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
EP0181351A4 (en) 1984-05-09 1989-06-21 Univ Australian METHOD FOR MODULATING IMMUNE REACTION.
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
JP3360899B2 (ja) 1993-10-08 2003-01-07 日本医薬品工業株式会社 癌予防・治療剤
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
EP0873414A1 (en) 1995-12-21 1998-10-28 Procur AB Galactopyranosides and their use
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
KR100252194B1 (ko) 1997-10-10 2000-04-15 박호군 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
EP1290952B1 (en) 2000-06-14 2005-03-30 Kao Corporation Compositions for taking dietary fibers
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
KR100594353B1 (ko) 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
AU2004229399B2 (en) 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CA2582428A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
ATE536177T1 (de) 2004-10-04 2011-12-15 Univ Minnesota Calixaren-basierte peptidkonformationsmimetika, verfahren zu ihrer verwendung und verfahren zu ihrer herstellung
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
AU2008219666A1 (en) * 2007-02-27 2008-09-04 Genentech, Inc. Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2008121768A2 (en) 2007-03-29 2008-10-09 University Of Tennessee Research Foundation Glycan-binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon
KR101074158B1 (ko) 2008-04-07 2011-10-17 재단법인 한국원자력의학원 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
KR101968370B1 (ko) 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Also Published As

Publication number Publication date
MX2015003416A (es) 2015-10-29
IL237752B (en) 2018-08-30
KR102207767B1 (ko) 2021-01-26
DK2900061T3 (da) 2020-03-02
CA2885970A1 (en) 2014-03-20
US20180236084A1 (en) 2018-08-23
BR112015005772A2 (pt) 2017-08-08
AU2013315019B2 (en) 2017-06-01
CN104812244A (zh) 2015-07-29
EP2900061A4 (en) 2016-07-06
US9872909B2 (en) 2018-01-23
JP2015528514A (ja) 2015-09-28
EP2900061B1 (en) 2020-01-22
ES2773921T3 (es) 2020-07-15
US10398778B2 (en) 2019-09-03
EP2900061A1 (en) 2015-08-05
US20140086932A1 (en) 2014-03-27
ZA201501914B (en) 2016-10-26
JP6415437B2 (ja) 2018-10-31
KR20150085508A (ko) 2015-07-23
CA2885970C (en) 2020-10-20
AU2013315019A1 (en) 2015-04-09
CN104812244B (zh) 2018-10-30
WO2014043708A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
MX374547B (es) Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer.
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
MX2019009437A (es) Tratamiento de mielosupresion.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
EA201590987A1 (ru) Соединения и способы их применения
ECSP12012349A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
ECSP12012348A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016500207A1 (en) Anti-infective compounds
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
EP4382535A3 (en) Compositions and methods for targeted cytokine delivery
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP4552698A3 (en) Methods of treating prostate cancer
MX2015003701A (es) Composiciones para tratamiento.
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX376782B (es) Métodos de administración de composiciones de amantadina.
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
MX2015007164A (es) Uso de estracto de fenogreco para mejorar la libido femenina.

Legal Events

Date Code Title Description
FG Grant or registration